Stryker slides as investors appear to de-risk despite upbeat positioning and reaffirmed outlook

Stryker Corporation (SYK) is down 4.7% today. Here is some analysis on what might have caused this price movement.

Analysis: A clear, single-company headline catalyst was not broadly evident from mainstream disclosures, so today’s drop looks most consistent with risk-off positioning and technical selling pressure after a recent chart breakdown. This could also reflect profit-taking and valuation sensitivity in large-cap medtech even as the company has recently reiterated its outlook and analysts have highlighted the name positively.

Details:

The company’s March 2026 investor materials reiterated its 2026 outlook, which can reduce “new news” support for the shares if investors pivot toward macro and positioning factors.

In the last week, multiple Wall Street notes reiterated positive stances and raised/maintained price targets, suggesting today’s move may not be driven by a fresh downgrade cycle.

Earlier in March, the stock traded below its 200-day moving average, a level that can trigger systematic or technically oriented selling and increase volatility.

This could be because investors rotated away from higher-multiple healthcare/medtech names during a broader market pullback, amplifying a downside move in a widely held large-cap stock.

Sources:

Stryker Investor Relations, TipRanks, Investing.com, Dividend Channel

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$SYK Insider Trading Activity

$SYK insiders have traded $SYK stock on the open market 35 times in the past 6 months. Of those trades, 0 have been purchases and 35 have been sales.

Here’s a breakdown of recent trading of $SYK stock by insiders over the last 6 months:

RONDA E STRYKER has made 0 purchases and 32 sales selling 1,020,000 shares for an estimated $366,325,409.
WILLIAM E JR BERRY (VP, Chief Accounting Officer) sold 1,953 shares for an estimated $713,801
JAMES ANDREW PIERCE (Group President) sold 475 shares for an estimated $175,214
PRESTON WENDELL WELLS (VP, Chief Financial Officer) sold 165 shares for an estimated $60,370

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$SYK Hedge Fund Activity

We have seen 985 institutional investors add shares of $SYK stock to their portfolio, and 1,145 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 5,493,352 shares (-74.6%) from their portfolio in Q4 2025, for an estimated $1,930,748,427
AUTO-OWNERS INSURANCE CO added 2,906,448 shares (+35047.0%) to their portfolio in Q4 2025, for an estimated $1,021,529,278
FMR LLC removed 2,163,324 shares (-42.1%) from their portfolio in Q4 2025, for an estimated $760,343,486
WELLINGTON MANAGEMENT GROUP LLP added 1,198,665 shares (+22.6%) to their portfolio in Q4 2025, for an estimated $421,294,787
FUNDSMITH LLP removed 903,782 shares (-19.7%) from their portfolio in Q4 2025, for an estimated $317,652,259
PRICE T ROWE ASSOCIATES INC /MD/ removed 879,884 shares (-8.0%) from their portfolio in Q4 2025, for an estimated $309,252,829
BLACKROCK, INC. added 720,608 shares (+2.7%) to their portfolio in Q4 2025, for an estimated $253,272,093

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$SYK Government Contracts

We have seen $44,349,534 of award payments to $SYK over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

MAKO 4 ROBOTIC SYSTEM: $3,643,551
MAKO 3 SURGICAL ROBOT: $950,000
4569335966!MAKO4-TKA-PKA-THA50: $920,000
SURGICAL SUPPLIES IM NAILING: $310,510
SURGICAL INSTRUMENTS: $299,425

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.

$SYK Congressional Stock Trading

Members of Congress have traded $SYK stock 7 times in the past 6 months. Of those trades, 3 have been purchases and 4 have been sales.

Here’s a breakdown of recent trading of $SYK stock by members of Congress over the last 6 months:

REPRESENTATIVE THOMAS H. KEAN, JR. has traded it 3 times. They made 0 purchases and 3 sales worth up to $150,000 on 01/23, 11/20, 09/12.
REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 3 times. They made 3 purchases worth up to $45,000 on 12/10, 11/18, 10/17 and 0 sales.
REPRESENTATIVE JULIA LETLOW sold up to $15,000 on 10/16.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$SYK Analyst Ratings

Wall Street analysts have issued reports on $SYK in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Wells Fargo issued a "Overweight" rating on 11/14/2025
BTIG issued a "Buy" rating on 11/14/2025
Barclays issued a "Overweight" rating on 10/22/2025
Evercore ISI Group issued a "Outperform" rating on 10/07/2025

To track analyst ratings and price targets for $SYK, check out Quiver Quantitative's $SYK forecast page.

$SYK Price Targets

Multiple analysts have issued price targets for $SYK recently. We have seen 11 analysts offer price targets for $SYK in the last 6 months, with a median target of $420.0.

Here are some recent targets:

Danielle Antalffy from UBS set a target price of $400.0 on 02/24/2026
Ryan Zimmerman from BTIG set a target price of $412.0 on 01/30/2026
Mike Matson from Needham set a target price of $454.0 on 01/30/2026
Lee Hambright from Bernstein set a target price of $465.0 on 01/09/2026
David Turkaly from Citizens set a target price of $440.0 on 12/19/2025
Richard Newitter from Truist Securities set a target price of $392.0 on 12/18/2025
Joanne Wuensch from Citigroup set a target price of $420.0 on 12/11/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.